Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 13, 2020

View Archived Issues

Enrollment ongoing in phase I/II ASPEN-02 study of ALX-148 plus azacytidine in MDS

Oncostellae initiates phase Ib/IIa study of OST-122 in ulcerative colitis

Venthera begins first-in-human trial of VT-30

Drug repurposing study suggests paromomycin as a dual targeting drug against SARS-CoV-2

FKBP9P1 lncRNA is upregulated in HNSCC and its knockdown inhibits malignant progression

Microbiome metabolite affects neuropathic pain

Prying the BBB back open for improved LSD treatment

Dosing starts in phase I study of AMP-945

PENELOPE-B study of palbociclib does not meet primary endpoint

Potential MND treatments move a step forward

Galectin-7, a new biomarker for pre-eclampsia

UBAP2 as potential therapeutic target in pancreatic cancer

FDA clears IND for trials of ASC-42 for NASH

FDA issues complete response letter for Avenue's intravenous tramadol

Sorrento licenses PSC's mesenchymal stem cells for COVID-19-associated ARDS

Pivotal trial of Dupixent in children with moderate to severe asthma meets primary endpoint

SynAct advances phase IIa study of AP-1189 in rheumatoid arthritis

AstraZeneca advances AZD-7442 into phase III for COVID-19

Memorial Sloan Kettering, HHS patent ADAM 17-binding molecules

Celltrion begins phase III postexposure prophylaxis trial of CT-P59 for COVID-19

Janssen Pharmaceutica discloses new MAP4K1 inhibitors

New HDAC6 inhibitors discovered at 2681603 Ontario

Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical present new ERK inhibitors

Axis Therapeutics collaborates with PharmaEssentia on TCR-T cell therapy in Taiwan

Registrational trial of penpulimab for nasopharyngeal cancer meets key endpoints

Promising cohort 2 data reported from pivotal study of Padcev in urothelial cancer

Topline data reported from EAP study with aviptadil for critical COVID-19

Phase I/II study of PLX-PAD for GvHD cleared to advance to cohort 2

New phase III trial evaluates hIVIG to treat COVID-19

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...